Lazard Asset Management’s BeOne Medicines ONC Stock Holding History
Bought
Maintained
Sold
Other funds holding ONC
BBA
Lazard Asset Management's ONC Position: Q3 2026 in Review
Lazard Asset Management increased its BeOne Medicines (ONC) stake by 30% in Q3 2026, buying an estimated $9.35M and bringing the position to 117,700 shares worth $43.1M. The position accounts for 0.06% of the portfolio, ranked #238.
Lazard Asset Management first reported a position in ONC in Q4 2017 and has held it in 11 quarters since. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.
- Lazard Asset Management held 117,700 shares of BeOne Medicines worth $43.1M as of Q3 2026.
- Lazard Asset Management bought 27,352 BeOne Medicines shares in Q3 2026, an estimated $9.35M.
- BeOne Medicines made up 0.06% of Lazard Asset Management's portfolio in Q3 2026, its #238 holding.
- Lazard Asset Management first reported a position in BeOne Medicines in Q4 2017 and has held it in 11 quarters since.
- 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.